Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Mar;84(5):680–685. doi: 10.1054/bjoc.2000.1639

Circumvention of ara-C resistance by aphidicolin in blast cells from patients with AML

J M Sargent 1, A W Elgie 1, C J Williamson 1, G M Lewandowicz 1, C G Taylor 1
PMCID: PMC2363802  PMID: 11237390

Abstract

Treatment failure in AML is often attributed to P-glycoprotein-associated multidrug resistance. However, the importance of increased DNA repair in resistant cells is becoming more apparent. In order to investigate the ability of the DNA repair inhibitor aphidicolin to modulate drug resistance, we continually exposed blasts cells, isolated from 22 patients with AML, to a variety of agents ± 15 μM aphidicolin for 48 hours. Cell survival was measured using the MTT assay. Overall, there was no significant effect of aphidicolin on sensitivity to daunorubicin, doxorubicin, etoposide or fludarabine. However, there was a marked increase in sensitivity to ara-C with a median 4.75-fold increase overall (range 0.8–80-fold;P< 0.005). The effect of aphidicolin was significantly greater in blast cells found resistant in vitro to ara-C (8.9-fold compared to 2.12-fold, P< 0.01). This observation was further validated by the correlation between ara-C LC 50 and extent of modulation effect (P< 0.05). Cells isolated from 10 cord blood samples were also tested in order to establish the haematological toxicity of combining ara-C and aphidicolin. The therapeutic index (LC 50 normal cells/tumour cells) for ara-C + aphidicolin was higher than that for ara-C alone suggesting no increased myelotoxicity for the combination. Increased cytotoxicity without increased haematotoxicity makes the combination of ara-C plus aphidicolin ideal for inclusion in future clinical trials. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: aphidicolin, DNA repair, drug resistance, AML, ara-C

Full Text

The Full Text of this article is available as a PDF (69.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aström M., Bodin L., Nilsson I., Tidefelt U. Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden. Br J Cancer. 2000 Apr;82(8):1387–1392. doi: 10.1054/bjoc.1999.1123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barnett D., Janossy G., Lubenko A., Matutes E., Newland A., Reilly J. T. Guideline for the flow cytometric enumeration of CD34+ haematopoietic stem cells. Prepared by the CD34+ haematopoietic stem cell working party. General Haematology Task Force of the British Committee for Standards in Haematology. Clin Lab Haematol. 1999 Oct;21(5):301–308. doi: 10.1046/j.1365-2257.1999.00253.x. [DOI] [PubMed] [Google Scholar]
  3. Barret J. M., Hill B. T. DNA repair mechanisms associated with cellular resistance to antitumor drugs: potential novel targets. Anticancer Drugs. 1998 Feb;9(2):105–123. doi: 10.1097/00001813-199802000-00001. [DOI] [PubMed] [Google Scholar]
  4. Braess J., Wegendt C., Feuring-Buske M., Riggert J., Kern W., Hiddemann W., Schleyer E. Leukaemic blasts differ from normal bone marrow mononuclear cells and CD34+ haemopoietic stem cells in their metabolism of cytosine arabinoside. Br J Haematol. 1999 May;105(2):388–393. [PubMed] [Google Scholar]
  5. Bramson J., Panasci L. Potentiation of chlorambucil toxicity in B-CLL lymphocytes using the DNA synthesis inhibitors aphidicolin and 1-beta-D-arabinofuranosylcytosine. Biochem Pharmacol. 1995 Jun 29;50(1):131–135. doi: 10.1016/0006-2952(95)00104-8. [DOI] [PubMed] [Google Scholar]
  6. Covelli A. Modulation of multidrug resistance (MDR) in hematological malignancies. Ann Oncol. 1999;10 (Suppl 6):53–59. [PubMed] [Google Scholar]
  7. Elgie A. W., Sargent J. M., Alton P., Peters G. J., Noordhuis P., Williamson C. J., Taylor C. G. Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML. Leuk Res. 1998 Apr;22(4):373–378. doi: 10.1016/s0145-2126(98)00011-3. [DOI] [PubMed] [Google Scholar]
  8. Freund A., Boos J., Harkin S., Schultze-Mosgau M., Veerman G., Peters G. J., Gescher A. Augmentation of 1-beta-D-arabinofuranosylcytosine (Ara-C) cytotoxicity in leukaemia cells by co-administration with antisignalling drugs. Eur J Cancer. 1998 May;34(6):895–901. doi: 10.1016/s0959-8049(97)10149-6. [DOI] [PubMed] [Google Scholar]
  9. Ghielmini M., Bosshard G., Capolongo L., Geroni M. C., Pesenti E., Torri V., D'Incalci M., Cavalli F., Sessa C. Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. Br J Cancer. 1997;75(6):878–883. doi: 10.1038/bjc.1997.155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Heim M. M., Eberhardt W., Seeber S., Müller M. R. Differential modulation of chemosensitivity to alkylating agents and platinum compounds by DNA repair modulators in human lung cancer cell lines. J Cancer Res Clin Oncol. 2000 Apr;126(4):198–204. doi: 10.1007/s004320050033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Klumper E., Ossenkoppele G. J., Pieters R., Huismans D. R., Loonen A. H., Rottier A., Westra G., Veerman A. J. In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia. Br J Haematol. 1996 Jun;93(4):903–910. doi: 10.1046/j.1365-2141.1996.d01-1742.x. [DOI] [PubMed] [Google Scholar]
  12. Kuwakado K., Kubota M., Bessho R., Kataoka A., Usami I., Lin Y. W., Okuda A., Wakazono Y. Augmentation by aphidicolin of 1-beta-D-arabinofuranosylcytosine-induced c-jun and NF-kappa B activation in a human myeloid leukemia cell line: correlation with apoptosis. Leuk Res. 1995 Sep;19(9):645–650. doi: 10.1016/0145-2126(95)00046-q. [DOI] [PubMed] [Google Scholar]
  13. Kuwakado K., Kubota M., Hirota H., Adachi S., Matsubara K., Kasai Y., Akiyama Y., Mikawa H. Aphidicolin potentiates apoptosis induced by arabinosyl nucleosides in human myeloid leukemia cell lines. Biochem Pharmacol. 1993 Dec 3;46(11):1909–1916. doi: 10.1016/0006-2952(93)90631-6. [DOI] [PubMed] [Google Scholar]
  14. Longley M. J., Pierce A. J., Modrich P. DNA polymerase delta is required for human mismatch repair in vitro. J Biol Chem. 1997 Apr 18;272(16):10917–10921. doi: 10.1074/jbc.272.16.10917. [DOI] [PubMed] [Google Scholar]
  15. McKenna S. L., Padua R. A. Multidrug resistance in leukaemia. Br J Haematol. 1997 Mar;96(4):659–674. doi: 10.1046/j.1365-2141.1997.d01-2095.x. [DOI] [PubMed] [Google Scholar]
  16. Mirzayans R., Enns L., Cubitt S., Karimian K., Radatus B., Paterson M. C. Effect of DNA polymerase inhibitors on repair of gamma ray-induced DNA damage in proliferating (intact versus permeable) human fibroblasts: evidence for differences in the modes of action of aphidicolin and 1-beta-D-arabinofuranosylcytosine. Biochim Biophys Acta. 1994 Oct 21;1227(1-2):92–100. doi: 10.1016/0925-4439(94)90112-0. [DOI] [PubMed] [Google Scholar]
  17. Moreland N. J., Illand M., Kim Y. T., Paul J., Brown R. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin. Cancer Res. 1999 May 1;59(9):2102–2106. [PubMed] [Google Scholar]
  18. Plunkett W., Gandhi V. Cellular pharmacodynamics of anticancer drugs. Semin Oncol. 1993 Feb;20(1):50–63. [PubMed] [Google Scholar]
  19. Sargent J. M., Elgie A. W., Williamson C. J., Taylor C. G. Aphidicolin markedly increases the in vitro sensitivity to ara-C of blast cells from patients with AML. Adv Exp Med Biol. 1999;457:567–570. doi: 10.1007/978-1-4615-4811-9_62. [DOI] [PubMed] [Google Scholar]
  20. Sargent J. M., Elgie A. W., Williamson C. J., Taylor C. G. Aphidicolin markedly increases the platinum sensitivity of cells from primary ovarian tumours. Br J Cancer. 1996 Dec;74(11):1730–1733. doi: 10.1038/bjc.1996.622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sargent J. M., Taylor C. G. Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukaemia. Br J Cancer. 1989 Aug;60(2):206–210. doi: 10.1038/bjc.1989.252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Sessa C., Zucchetti M., Davoli E., Califano R., Cavalli F., Frustaci S., Gumbrell L., Sulkes A., Winograd B., D'Incalci M. Phase I and clinical pharmacological evaluation of aphidicolin glycinate. J Natl Cancer Inst. 1991 Aug 21;83(16):1160–1164. doi: 10.1093/jnci/83.16.1160. [DOI] [PubMed] [Google Scholar]
  23. Sherwood S. W., Schimke R. T. Cell cycle analysis of apoptosis using flow cytometry. Methods Cell Biol. 1995;46:77–97. doi: 10.1016/s0091-679x(08)61925-1. [DOI] [PubMed] [Google Scholar]
  24. Von Hoff D. D. There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res. 1998 May;4(5):1079–1086. [PubMed] [Google Scholar]
  25. Wood R. D. DNA repair in eukaryotes. Annu Rev Biochem. 1996;65:135–167. doi: 10.1146/annurev.bi.65.070196.001031. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES